^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Excerpt:
...- Must have evidence of positive c-Met protein expression by IHC from either local data or the results of molecular pre-screening evaluations;Must haved evidence of MET exon 14 skipping alterations in blood and/or tissue samples....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Published date:
04/11/2023
Excerpt:
In this two-part multicenter phase Ib study, eligible patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation were enrolled...Only one partial response (PR) patient was observed at a dose of 600 mg QD in Part A. In Part B, DCR was 75.0% (3/4, 95% CI 19.4–99.4%).
DOI:
https://doi.org/10.1186/s12885-022-10500-y
Trial ID: